Ken Drazan, ArsenalBio CEO
Cell therapy startup ArsenalBio raises $325M as it runs early solid tumor trials
CAR-T cell therapy startup Arsenal Biosciences has reeled in a $325 million Series C as it works through two early-stage trials in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
